Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
✍ Scribed by Emmanuel Mitry; Pascal Hammel; Gaël Deplanque; Françoise Mornex; Philippe Levy; Jean-François Seitz; Alain Moussy; Jean-Pierre Kinet; Olivier Hermine; Philippe Rougier; Eric Raymond
- Publisher
- Springer
- Year
- 2010
- Tongue
- English
- Weight
- 415 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## BACKGROUND. In early phase I1 trials in advanced pancreatic cancer, gemcitabine demonstrated modest antitumor activity. The investigators in these studies reported that gemcitabine should be studied further in view of the degree and frequency of symptomatic improvement observed, the durability o
## BACKGROUND. In early phase I1 trials in advanced pancreatic cancer, gemcitabine demonstrated modest antitumor activity. The investigators in these studies reported that gemcitabine should be studied further in view of the degree and frequency of symptomatic improvement observed, the durability o
## Purpose: To evaluate whether celecoxib alters the conversion of gemcitabine into its active metabolite, difluorodeoxycytidine triphosphate (dfdctp), in peripheral blood mononuclear cells (pbmcs). ## Methods: Patients with advanced pancreatic cancer who had not received chemotherapy and had acc